Cell Signaling Technology

Product Pathways - PI3K / Akt Signaling

SignalSilence® GSK-3α siRNA Kit #6525

Products Included No. Quantity Isotype Assay
SignalSilence® GSK-3α siRNA I 6312 10 µM in 150 µl 50 Transfections
SignalSilence® GSK-3α siRNA II 6524 10 µM in 150 µl 50 Transfections
GSK-3α Antibody 9338 40 µl Rabbit IgG 4 Western mini blots

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells following transfection with non-targeted SignalSilence® Control siRNA #6201 (-), SignalSilence® GSK-3α siRNA II (+) or SignalSilence® GSK-3α siRNA I (+), using GSK-3α Antibody and β-Actin (13E5) Rabbit mAb #4970. GSK-3α Antibody confirms silencing of GSK-3α expression, while the β-Actin (13E5) Rabbit mAb is used to control for loading and specificity of GSK-3α siRNA.

Description

SignalSilence® GSK-3α siRNA Kit from Cell Signaling Technology (CST) allows the researcher to specifically inhibit GSK-3α expression. The kit utilizes RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA kits are rigorously tested in-house and have been shown to reduce target protein expression. SignalSilence® GSK-3α siRNA Kit includes GSK-3α siRNA I and II and a target-specific GSK-3α antibody to confirm the silencing of GSK-3α expression by western analysis.

Directions for Use

CST recommends transfection with 100 nM GSK-3α siRNA 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Background

Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3 kinase/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).

  1. Welsh, G.I. et al. (1996) Trends Cell. Biol. 6, 274-279.
  2. Srivastava, A.K. and Pandey, S.K. (1998) Mol. Cell. Biochem. 182, 135-141.
  3. Cross, D.A. et al. (1995) Nature 378, 785-789.
  4. Nusse, R. (1997) Cell 89, 321-323.
  5. Diehl, J.A. et al. (1998) Genes Dev. 12, 3499-3511.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Protocols

Companion Products

Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products